Nuvalent (NUVL) Income from Continuing Operations (2020 - 2026)
Nuvalent (NUVL) posted Income from Continuing Operations of 109279000.0 for Q1 2026, down 277.94% on a QoQ basis from 28914000.0 in Q4 2025, and down 29.2% year-over-year from 154346436.97 in Q1 2025.
Nuvalent (NUVL) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Nuvalent's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 109279000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 29.2% year-over-year to 109279000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 360283000.0 (down 19.75% YoY) and the FY2025 annual result came in at 335586000.0, down 28.7% from the prior year.
- Income from Continuing Operations was 109279000.0 for Q1 2026 at Nuvalent, down from 28914000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 18571000.0 in Q1 2022 and bottomed at 122437000.0 in Q3 2025.
- A 5-year average of 54003235.29 and a median of 38292000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 201.38% — and 2025, when it soared 61.33%.
- Nuvalent's Income from Continuing Operations stood at 27462000.0 in 2022, then tumbled by 39.44% to 38292000.0 in 2023, then tumbled by 95.24% to 74763000.0 in 2024, then surged by 61.33% to 28914000.0 in 2025, then plunged by 277.94% to 109279000.0 in 2026.
- Business Quant data shows NUVL's Income from Continuing Operations at 109279000.0 in Q1 2026, 28914000.0 in Q4 2025, and 122437000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | -109.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -109.28 Mn |
| Dec 31, 2025 | -28.91 Mn |
| Sep 30, 2025 | -122.44 Mn |
| Jun 30, 2025 | -99.65 Mn |
| Mar 31, 2025 | -84.58 Mn |
| Dec 31, 2024 | -74.76 Mn |
| Sep 30, 2024 | -84.35 Mn |
| Jun 30, 2024 | -57.17 Mn |
| Mar 31, 2024 | -44.48 Mn |
| Dec 31, 2023 | -38.29 Mn |
| Sep 30, 2023 | -33.65 Mn |
| Jun 30, 2023 | -29.09 Mn |
| Mar 31, 2023 | -25.19 Mn |
| Dec 31, 2022 | -27.46 Mn |
| Sep 30, 2022 | -20.58 Mn |
| Jun 30, 2022 | -19.60 Mn |
| Mar 31, 2022 | -18.57 Mn |
| Dec 31, 2021 | -40.78 Mn |
| Sep 30, 2021 | -12.43 Mn |
| Jun 30, 2021 | -9.85 Mn |